NCT04561128已完成1 期
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administered SHR-1819 in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Adverse events
研究概览
简要总结
This is a single center, randomized, double-blind, placebo-controlled, single dose escalation phase 1 study.
详细描述
This is a single center, randomized, double-blind, placebo-controlled, single dose escalation phase 1 study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous administered SHR-1819 in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Ability to understand the trial procedures and possible adverse events, volunteers to participate in the trial, and provides written informed consent.
- •Be able to comply with all the requirements and able to complete the study.
- •Male or female aged between 18 years and 55 years (inclusive) at the date of signed consent form.
- •No clinically significant abnormalities in medical history, general physical examination, vital signs, and laboratory tests.
- •Men and women of childbearing potential (WOCBP) must agree to take effective contraceptive methods and have no plan to have a child from signing the consent form to 16 weeks after IP administration.
排除标准
- •Positive hepatitis B virus (HBsAg), hepatitis C virus (HCV-Ab), human immunodeficiency virus (HIV-Ab), or QuantiFERON-TB Gold tests at screening;
- •Participation in clinical trials of other investigational drugs or medical devices within 3 months prior to screening (according to the date of signed consent form), or in the follow-up period of a clinical study
- •Severe injuries or surgeries within 6 months before screening or plan to do surgeries during the trial
- •Any other circumstances that, in the investigator's judgment, may increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response
研究组 & 干预措施
SHR-1819
Experimental
Experimental: SHR-1819
干预措施: SHR-1819 (Drug)
Placebo
Placebo Comparator
Placebo comparator: placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Adverse events
时间窗: Start of Treatment to end of study (approximately 13 weeks)
Incidence and severity of adverse events
次要结局
- Pharmacokinetics-AUC0-last(Start of Treatment to end of study (approximately 13 weeks))
- Pharmacokinetics-Vz/F(Up to 13 weeks)
- Pharmacokinetics-t1/2(Up to 13 weeks)
- Pharmacokinetics-AUC0-inf(Start of Treatment to end of study (approximately 13 weeks))
- Pharmacokinetics-Tmax(Up to 13 weeks)
- Pharmacokinetics-Cmax(Up to 13 weeks)
- Pharmacokinetics-CL/F(Up to 13 weeks)
- Change from baseline to end of treatment for TARC/CCL17(Up to 13 weeks)
- Change from baseline to end of treatment for IgE(Up to 13 weeks)
- Immunogenicy of SHR-1819 after administration(Up to 13 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Escalating Single Dose Study of Epsi- Gam in Healthy Normal SubjectsAllergy and ImmunologyNCT02559258Tunitas Therapeutics, Inc.5
招募中
1 期
Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy WomenVaginitisVaginal DiseaseBacterial InfectionsInfection, BacterialBacterial VaginosisNCT05587283AtoGen Co. Ltd24
已完成
1 期
Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese ParticipantsAcute Bacterial Skin and Skin Structure Infection (ABSSSI)Prosthetic Joints Infection (PJI)NCT06394518TenNor Therapeutics Inc.32
已完成
1 期
A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM SubjectsHealthy SubjectsT2DM (Type 2 Diabetes Mellitus)ObesityNCT05943886Dongguan HEC Biopharmaceutical R&D Co., Ltd.164
已完成
1 期
A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271PneumoniaNCT02724085Tetraphase Pharmaceuticals, Inc.57